Navigation Links
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
Date:7/28/2011

inute and 1.5% reported at the end of the first 24 weeks of the Phase 1/2 trial.  Stair climb and pulmonary function are secondary and tertiary endpoints, respectively, in the ongoing prospective Phase 3 trial.
  • The data from the extension study to date support 6-minute walk distance as the primary endpoint and patients with baseline walk distance <325 meters as an entry criteria in the ongoing GALNS Phase 3 trial, given the large and durable effect of the drug on these measures in this population.

  • Simon Jones, Consultant in Paediatric Metabolic Medicine, St. Mary's Hospital, Manchester UK commented, "I'm pleased with the outcome of the GALNS program to date.  The longer-term data look good with sustained improvements in endurance and pulmonary function.  Patients feel stronger and function better than I expected.  All in all, we look forward to the results of the Phase 3 study as it is well designed and will, if successful, support introduction of an important product to patients in need."

    Hank Fuchs, M.D., Chief Medical Officer of BioMarin added, "It's remarkable that improvements in endurance are sustained in spite of the severe and progressive nature of Morquio syndrome.  Patients with Morquio syndrome can miss therapy, for example, due to the need for corrective surgery.  In spite of that, resumption of therapy returns patients to their original state of health or better."Table 1 – Summary of Efficacy Results Through Week 24 of MOR-100 Extension Study Statistic

    MOR-002

    Week 24

    MOR-002

    Week 36

    MOR-100

    Week 0

    MOR-100

    Week 12

    MOR-100

    Week 24Dose

    1.0 mg/kg

    2.0 mg/kg

    1.0 mg/kg for previous 36-48 weeks, Begin 2.0 mg/kg

    2.0 mg/kg

    2.0 mg/kgENDURANCE6 Minute Walk Test – change from Baseline (meters)

    N

    Mean

    (Std. Dev.)

    Median

    16

    17.3

    (74.0)'/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
    2. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
    3. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
    4. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
    5. BioMarin to Present at the Barclays Capital Global Healthcare Conference
    6. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
    7. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
    8. BioMarin to Present at the Morgan Stanley Healthcare Conference
    9. BioMarin to Present at the Baird Healthcare Conference
    10. BioMarin to Present at the Jefferies Healthcare Conference
    11. BioMarin to Present at the Goldman Sachs Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
    (Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
    (Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
    (Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
    ... , MORRISVILLE, N.C. , April 23 Asymchem Laboratories ... as Director of Formulation Development, Dr. Pingzhong Huang as Director of Chemical ... Development. , , , ... (George) Xu joined Asymchem on February 1, 2010 .  He ...
    ... ... Awards Program recognizes these organizations for their outstanding innovations and excellence in the use ... research, and clinical trials. , ... Needham, Mass. (PRWEB) April 23, 2010 -- Bio-IT World magazine announced ...
    ... ... ISSSEEM conference will be of interest only to those who are going to ... live a life of happiness and value.” The International Society for ... annual conference, Evidence-based Spirituality for the 21st Century, June 25-29, 2010 at the ...
    Cached Biology Technology:Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 3BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 4BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 5BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 620th Annual ISSSEEM Conference &#8211; Evidence-based Spirituality for the 21st Century 220th Annual ISSSEEM Conference &#8211; Evidence-based Spirituality for the 21st Century 3
    (Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
    (Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
    (Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
    Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... Technology and Society Forum presentation on March 23, 2011 ... University Professor Sheena Iyengar, will address the psychological and ... her discipline-spanning research. Her talk, "The ... choice and freedom, and why one doesn,t always complement ...
    ... WASHINGTON, D.C. (March 8, 2011) -- Researchers at the ... of Texas at Dallas are reporting today at the ... how they are using a novel 3D cell imaging ... transport, providing a solution to this fundamental problem in ...
    ... blood cell production and function will today be awarded ... Council,s (NHMRC) program grants scheme. The nine ... securing $107 million in program grant funding will be ... the Federal Minister for Mental Health and Ageing, the ...
    Cached Biology News:Columbia professor to discuss good, bad aspects of choice at NJIT March 23 talk 2$38.4M NHMRC program grants extend cancer and blood cell research 2
    ...
    Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
    ... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
    ... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
    Biology Products: